{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+agent&page=2",
    "query": {
      "intervention": "Human agent",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+agent&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T17:28:25.996Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04052698",
      "title": "Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Diseases"
      ],
      "interventions": [
        {
          "name": "Wilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2020-06-18",
      "completion_date": "2022-04-23",
      "has_results": true,
      "last_update_posted_date": "2023-10-25",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04052698"
    },
    {
      "nct_id": "NCT03615326",
      "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Neoplasms",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "S-1",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 738,
      "start_date": "2018-10-05",
      "completion_date": "2025-11-12",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03615326"
    },
    {
      "nct_id": "NCT03821935",
      "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "Livmoniplimab",
          "type": "DRUG"
        },
        {
          "name": "Budigalimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 364,
      "start_date": "2019-02-21",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 21,
      "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 16 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03821935"
    },
    {
      "nct_id": "NCT04468958",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV2"
      ],
      "interventions": [
        {
          "name": "SAB-185",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-07-01",
      "completion_date": "2020-12-23",
      "has_results": false,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 3,
      "location_summary": "Wichita, Kansas • Syracuse, New York • San Antonio, Texas",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04468958"
    },
    {
      "nct_id": "NCT05933525",
      "title": "Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diarrhea",
        "Travelers Diarrhea",
        "Infectious Diarrhea"
      ],
      "interventions": [
        {
          "name": "Travelan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Immuron Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 63,
      "start_date": "2023-05-29",
      "completion_date": "2024-12-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05933525"
    },
    {
      "nct_id": "NCT04495738",
      "title": "Infant Formula and Toddler Drink Feeding Intervention",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Respiratory Infections in Children"
      ],
      "interventions": [
        {
          "name": "Control Infant Formula",
          "type": "OTHER"
        },
        {
          "name": "Control Toddler Drink",
          "type": "OTHER"
        },
        {
          "name": "Experimental Infant Formula",
          "type": "OTHER"
        },
        {
          "name": "Experimental Toddler Drink",
          "type": "OTHER"
        },
        {
          "name": "Supplemental Formula for HM Group",
          "type": "OTHER"
        },
        {
          "name": "Toddler Drink for HM group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abbott Nutrition",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "14 Days",
        "sex": "ALL",
        "summary": "Up to 14 Days"
      },
      "enrollment_count": 168,
      "start_date": "2020-08-10",
      "completion_date": "2021-04-12",
      "has_results": false,
      "last_update_posted_date": "2021-05-14",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 27,
      "location_summary": "Dothan, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 22 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Grand Junction",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04495738"
    },
    {
      "nct_id": "NCT02855450",
      "title": "Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "rhNGF",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-12",
      "completion_date": "2018-05",
      "has_results": true,
      "last_update_posted_date": "2020-11-25",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02855450"
    },
    {
      "nct_id": "NCT03118349",
      "title": "Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Carcinoma",
        "Tumors That Express CA 19-9"
      ],
      "interventions": [
        {
          "name": "MVT-1075",
          "type": "DRUG"
        },
        {
          "name": "MVT-5873",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech Research & Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2017-06-01",
      "completion_date": "2018-04-11",
      "has_results": false,
      "last_update_posted_date": "2023-04-21",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • New York, New York",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03118349"
    },
    {
      "nct_id": "NCT00775424",
      "title": "PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "PENNVAX-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GENEVAX IL-12-4532",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PLACEBO",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-15 adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 38,
      "start_date": "2008-09",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2016-08-25",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00775424"
    },
    {
      "nct_id": "NCT07164313",
      "title": "A Study of ZW251 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Squamous Cell Non-Small Cell Lung Cancer",
        "Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "ZW251",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zymeworks BC Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-10-21",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-09-07T17:28:25.996Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Santa Monica, California • Louisville, Kentucky + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07164313"
    }
  ]
}